Common and Less Common Side Effects The most frequently reported side effects are digestive and may include nausea, vomiting, diarrhoea, constipation, abdominal discomfort, and reduced appetite
Weight loss among those who received tirzepatide was an average loss of 15% to 20% of their starting body weight over 72 weeks, about 16.5 months
Besides GLP-1s and insulin, another peptide approved by the FDA is tesamorelin, which is a synthetic growth hormone
108 TelenM
However, the main concern is its force is too strong to discount that possibility
The GLP1R rs6923761 variant and GIPR rs1800437 polymorphism affect semaglutide receptor sensitivity, meaning two patients on the same dose may experience different appetite suppression timelines